Canada Pension Plan Investment Board Acquires Shares of 798,740 Edwards Lifesciences Corporation $EW

Key Points

• Canada Pension Plan Investment Board acquired 798,740 Edwards Lifesciences shares worth approximately $72.3 million, giving it a 0.14% stake. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus a $0.74 consensus estimate and $1.74 billion in revenue, up 13.6% year over year.
• Analyst sentiment is generally positive: the stock carries a “Moderate Buy” consensus rating and a $100.27 average price target, compared with its recent opening price of $89.97.

Canada Pension Plan Investment Board acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 798,740 shares of the medical research company's stock, valued at approximately $72,254,000. Canada Pension Plan Investment Board owned about 0.14% of Edwards Lifesciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. TrinityBridge Ltd bought a new stake in Edwards Lifesciences in the 2nd quarter worth about $27,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $26,000. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $27,000. Finally, JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,857 shares of company stock worth $170,305 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 0.9%

EW opened at $89.97 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market cap of $51.81 billion, a price-to-earnings ratio of 51.71, a PEG ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company's 50-day moving average price is $89.48 and its two-hundred day moving average price is $84.99.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Evercore reiterated an "outperform" rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source